BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Antengene Secures Expanded Approvals For Xpovio In Hong Kong Across Multiple Myeloma And DLBCL

- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for mul...

December 04, 2025 | News

Aurigene Oncology Reports Strong Early Phase One Results For AUR112 In Relapsed And Refractory Lymphomas

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, announced initial clinical results...

December 04, 2025 | News

AdvanCell Launches Theraphase Two Expansion To Optimise Dosing For ADVC001 Across Key Prostate Cancer Settings

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will ...

December 04, 2025 | News

Antengene Secures NMPA Approval for IND of CLINCH Two Combination Study in Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, develop...

December 03, 2025 | News

Fujitsu Develops Multi AI Agent Collaboration Technology for Secure and Resilient Supply Chains

Fujitsu Limited announced the development of a multi-AI agent collaboration technology that enables secure collaboration and swift response to changin...

December 02, 2025 | News

Generate Plans Global Phase 3 Trials for AI Engineered GB 0895 in Severe Asthma

Generate:Biomedicines ("Generate") announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in appr...

December 02, 2025 | News

IDEAYA Moves IDE034 Into Clinic Following FDA Clearance and Strong B7H3 PTK7 Co Expression

B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at approximately 30%, 46%, and 27%, r...

December 02, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

Gan & Lee Launches Third Phase 3 Trial of Once-Monthly GLP-1 Bofanglutide for Long-Term Weight Maintenance

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of...

November 28, 2025 | News

Sanyou Bio Partners With FatiAbGen to Strengthen Korean Market Presence and Expand Global Biopharma Reach

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and South Korea's FatiAbGen Co., Ltd. jointly announced the signing of a...

November 28, 2025 | News

HKeyBio Expands Its Autoimmune and Allergy R&D Capabilities With HKEY-AIDMD 3.0 Platform Upgrade

The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBi...

November 28, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

Teijin Pharma to Receive $5M Milestone as Bioprojet Advances Novel Narcolepsy Candidate to Phase 1

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that it will receive in Q4 2025 a milestone paym...

November 28, 2025 | News

Stay Connected